

UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
United States Patent and Trademark Office
Washington, D.C. 20231

Paper No. 32

GENZYME CORPORATION C/O FISH & RICHARDSON, PC FISH & RICHARDSON, PC 225 FRANKLIN STREET BOSTON MA 02110-2804 **COPY MAILED**

JUN 2 0 2002

In re Application of Katherine Gordon and Suzanne Groet Application No. 07/839,194 Filed: February 20, 1992 Attorney Docket No. IG5-4.4 OFFICE OF PETITIONS

DECISION ON RENEWED PETITION

Title: TRANSGENIC ANIMALS SECRETING

DESIRED PROTEINS INTO MILK

This is a decision on the renewed petition filed on February 8, 20022, pursuant to 37 C.F.R. §1.137(b)², to revive the above-identified application.

The renewed petition is DISMISSED.

Any request for reconsideration of this decision must be submitted within TWO (2) MONTHS from the mail date of this decision. Extensions of time under 37 CFR 1.136(a) are permitted. The reconsideration request should include a cover letter entitled "Renewed Petition under 37 CFR 1.137(b)."

The above-identified application became abandoned for failure to reply to the final office action, mailed on January 30, 2001, which set a period for reply of three (3) months. No reply was received. Furthermore, no extensions of time were received. Accordingly, the above-identified application became abandoned on May 1, 2001. A Notice of abandonment was mailed on April 5, 2002.

The original petition, received on September 6, 2001, was dismissed by a decision mailed on November 6, 2001, for failure to submit a terminal disclaimer.

With the instant petition, the petitioner has submitted a terminal disclaimer. Unfortunately, the terminal disclaimer does not contain the necessary language. Specifically, the terminal disclaimer fails to set forth the appropriate term. Consequently, this petition cannot be granted. Terminal Disclaimer form PTO/SB/63 has been enclosed for petitioner's convenience. It is recommended that this form be used on second renewed petition to avoid further deficiencies.

Further correspondence with respect to this matter should be addressed as follows:

By mail:

Commissioner for Patents

Box DAC

Washington, DC 20231

2 A grantable petition pursuant to 37 CFR 1.137(b) must be accompanied by:

(1) The reply required to the outstanding Office action or notice, unless previously filed;

(2) The petition fee as set forth in § 1.17(m);

(4) Any terminal disclaimer (and fee as set forth in § 1.20(d)) required pursuant to paragraph (d) of this section.

¹ The petition contains a certificate of mailing dated January 3, 2002.

⁽³⁾ A statement that the entire delay in filing the required reply from the due date for the reply until the filing of a grantable petition pursuant to this paragraph was unintentional. The Commissioner may require additional information where there is a question whether the delay was unintentional, and;

By FAX:

المرازم

(703) 308-6916 Attn: Office of Petitions

By hand:

Office of Petitions 2201 South Clark Place Crystal Plaza 4, Suite 3C23 Arlington, VA 22202

Telephone inquiries specific to this decision should be directed to Petitions Attorney Paul Shanoski at (703) 305-

Paul Shanoski **Petitions Attorney** Office of Petitions

Office of the Deputy Commissioner for Patent Examination Policy

Encl.:

Form PTO/SB/63

Summary of the Privacy Act of 1974